Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Swedish Neurofibromatosis Center, |
RCV000857311 | SCV000996299 | likely pathogenic | Neurofibromatosis, type 2 | 2019-10-18 | criteria provided, single submitter | clinical testing | CLINICAL: a.Bilateral vestibular schwannomas, tinnitus age 8. PP4 b. Assumed de novo. PM6 VARSOME: a. Functional domain. PM1 b. Absent in population. PM2 c. Pathogenic in silico. PP3 |
Labcorp Genetics |
RCV000857311 | SCV001210152 | uncertain significance | Neurofibromatosis, type 2 | 2019-12-03 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with NF2-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces leucine with proline at codon 214 of the NF2 protein (p.Leu214Pro). The leucine residue is highly conserved and there is a moderate physicochemical difference between leucine and proline. |
Genome- |
RCV000857311 | SCV002045401 | uncertain significance | Neurofibromatosis, type 2 | 2021-11-07 | criteria provided, single submitter | clinical testing |